| NCT06679582 | Luveltamab Tazevibulin (STRO-002) in Infants and Children < 12 Years of Age With Relapsed/Refractory CBFA2T3::GLIS2 AML | TERMINATED | PHASE1, PHASE2 | 2024-12-04 | 2025-06-01 | 2025-06-01 |
| NCT06555263 | Study to Investigate Luveltamab Tazevibulin in Adults With Advanced or Metastatic Non-small Cell Lung Cancer | WITHDRAWN | PHASE2 | 2024-08-21 | 2025-05-01 | 2025-05-01 |
| NCT05870748 | REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1 | TERMINATED | PHASE2, PHASE3 | 2023-07-12 | 2025-08-26 | 2025-08-26 |
| NCT05200364 | A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer | TERMINATED | PHASE1 | 2022-03-22 | 2025-06-01 | 2025-06-01 |
| NCT03748186 | Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers | COMPLETED | PHASE1 | 2019-02-01 | 2024-06-04 | 2024-06-04 |
| NCT03424603 | Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies | COMPLETED | PHASE1 | 2018-02-22 | 2024-03-15 | 2024-02-15 |